Clinical Report: Endothelial Keratoplasty of the Descemet Membrane in Uveal Melanoma Patients Following Radiation Treatment
Overview
This study evaluates the outcomes of Descemet membrane endothelial keratoplasty (DMEK) in patients with uveal melanoma who have undergone radiation therapy. Results indicate that while DMEK can improve visual acuity, it is associated with higher postoperative risks.
Background
Uveal melanoma is the most prevalent primary intraocular tumor in adults, and its treatment often involves radiation therapy, which can lead to complications such as corneal endothelial disorders. DMEK has emerged as a viable surgical option for addressing these complications, potentially improving visual outcomes in affected patients. Understanding the efficacy and risks of DMEK in this context is crucial for optimizing patient care.
Data Highlights
No numerical data available in the source material.
Key Findings
DMEK was performed on 9 eyes from 9 patients after radiation therapy for uveal melanoma.
All patients underwent a single DMEK procedure with a graft minimum endothelial cell density of 2000 cells/mm².
Postoperative evaluations were conducted at 1, 3, 12, and 24 months, assessing visual acuity and corneal health.
Higher-than-usual postoperative risks included rebubbling (55.6%) and IOP elevation (55.6%), with 16.7% developing post-DMEK glaucoma.
The 2-year graft failure incidence was reported at 25%, with no local intraocular tumor recurrences observed during follow-up.
Clinical Implications
Clinicians should consider the potential benefits of DMEK for patients with corneal endothelial disorders following radiation therapy for uveal melanoma. However, they must also be vigilant about the increased risk of postoperative complications, including elevated intraocular pressure and graft failure.
Conclusion
DMEK presents a promising option for visual rehabilitation in patients post-radiation for uveal melanoma, but careful patient selection and management of postoperative risks are essential.
